title: The effect of simvastatin treatment on the amyloid precursor protein and brain cholesterol metabolism in patients with Alzheimer's disease.
abstract: During the last years, several clinical studies have been published trying to elucidate the effect of statin treatment on amyloid precursor protein (APP) processing and metabolism of brain cholesterol in Alzheimer's disease (AD) in humans. We present an open biochemical study where 19 patients with AD have been treated with simvastatin (20 mg/day) for 12 months. The aim was to further investigate the effect of simvastatin treatment on cerebrospinal fluid (CSF) biomarkers of APP processing, AD biomarkers as total tau and tau phosphorylated at threonine 181, brain cholesterol metabolism as well as on cognitive decline in patients with AD. Despite biochemical data suggesting that treatment with 20 mg/day of simvastatin for 12 months does affect the brain cholesterol metabolism, we did not find any change in CSF or plasma levels of beta-amyloid (Abeta)(1-42). However, by analysis of APP isoforms, we found that statin treatment may favor the nonamyloidogenic pathway of APP processing. The relevance and mechanism between statin treatment and AD has to be further elucidated by using statins of different lipophility in different dosages over a longer period of time.
authors.affiliation: Section of Experimental Neurochemistry, Institute of Clinical Neuroscience, Göteborg University, Göteborg, Sweden. kina.hoglund@neuro.gu.se
authors.forename: K
authors.initials: K
authors.lastname: Hoglund
authors.forename: K M
authors.initials: KM
authors.lastname: Thelen
authors.forename: S
authors.initials: S
authors.lastname: Syversen
authors.forename: M
authors.initials: M
authors.lastname: Sjogren
authors.forename: K
authors.initials: K
authors.lastname: von Bergmann
authors.forename: A
authors.initials: A
authors.lastname: Wallin
authors.forename: E
authors.initials: E
authors.lastname: Vanmechelen
authors.forename: H
authors.initials: H
authors.lastname: Vanderstichele
authors.forename: D
authors.initials: D
authors.lastname: Lutjohann
authors.forename: K
authors.initials: K
authors.lastname: Blennow
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000134:cerebrospinal fluid / Q000188:drug therapy*; D016564:Amyloid beta-Protein Precursor / Q000378:metabolism*; D000924:Anticholesteremic Agents / Q000008:administration & dosage*; D015415:Biomarkers / Q000134:cerebrospinal fluid; D001923:Brain Chemistry / Q000187:drug effects*; D002784:Cholesterol / Q000378:metabolism*; D003071:Cognition; D003072:Cognition Disorders / Q000134:cerebrospinal fluid / Q000188:drug therapy; D005260:Female; D006801:Humans; D008055:Lipids / Q000097:blood; D008297:Male; D010766:Phosphorylation; D019821:Simvastatin / Q000008:administration & dosage*; D013261:Sterols / Q000097:blood / Q000134:cerebrospinal fluid; D016875:tau Proteins / Q000134:cerebrospinal fluid
chemical_list: D016564:Amyloid beta-Protein Precursor; D000924:Anticholesteremic Agents; D015415:Biomarkers; D008055:Lipids; D013261:Sterols; D016875:tau Proteins; D002784:Cholesterol; D019821:Simvastatin